Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Arthritis Research & Therapy|January 13, 2018
Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritisChi Chiu Mok, Samar Soliman, Ling Yin Ho, et al.
The Open Rheumatology Journal|December 18, 2008
Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective studyLing Yin Ho, Chi Chiu Mok, Chi Hung To, et al.
Medicine|July 17, 2007
Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative studyChi Chiu Mok, Ka Hang Tong, Chi Hung To, et al.
Annals of the Rheumatic Diseases|May 26, 2020
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritisChi Chiu Mok, Ling Yin Ho, Shirley King Yee Ying, et al.
Annals of the Rheumatic Diseases|September 19, 2019
Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trialChi Chiu Mok, Kwok Hung Chan, Ling Yin Ho, et al.
Arthritis Care & Research|October 5, 2010
Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritisChi Chiu Mok, Gary Tin Choi Ko, Ling Yin Ho, et al.
Bone|February 25, 2021
Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trialChi Chiu Mok, Ling Yin Ho, Stella Mei Tik Leung, et al.
Annals of the Rheumatic Diseases|December 29, 2010
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trialChi Chiu Mok, King Yee Ying, Chi Hung To, et al.
Clinical and Experimental Rheumatology|February 20, 2025
Tixagevimab-cilgavimab for the prevention of COVID-19: real-world experience in patients with rheumatic diseases receiving rituximabChi Chiu Mok, Moon Ho Leung, Ka Man Chan, et al.
Pageof 3